Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Moderna has developed the first experimental coronavirus vaccine, but an approved treatment is more than a year away. Photo: David L. Ryan/The Boston Globe via Getty Images

A healthy U.S. volunteer received the first dose of an experimental coronavirus vaccine, a potential defense against the virus if it becomes a long-term threat.

Where it stands: The trial will ultimately give 45 volunteers two doses about 28 days apart in order to test the vaccine's effectiveness in protecting the subjects against COVID-19. If successful, several more trials with larger subject groups will be needed to prove whether there are common side effects.

Context: The vaccine candidate, code-named mRNA-1273, was developed by the National Institutes of Health and Massachusetts-based biotechnology company Moderna Inc.

  • Several other vaccines from researchers and companies around the world are in development.

What to watch: Even if the trial is successful, a vaccine for mass production and distribution worldwide will likely not be available for 12–18 months, said Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases.

Go deeper

First look: Biden's economic case for green cards

Photo: Win McNamee/Getty Images

The White House Council of Economic Advisors (CEA) is promoting the economic benefits and costs of providing green cards to millions of unauthorized immigrants in a blogpost being released on Friday, according to a draft provided to Axios.

Why it matters: The post comes as the fate of millions of immigrants, including those with Temporary Protected Status or DACA protections, rests with Congress — and the Senate parliamentarian.

Ina Fried, author of Login
11 mins ago - Technology
Column / Signal Boost

Facebook's social balance is in the red

Illustration: Megan Robinson/Axios

Facebook is essential to our lives. Facebook is ruining our lives. Holding both these truths at once will make your head hurt.

While covering the Olympics in Tokyo, I spent a ton of time on Facebook. Each day, during several hourlong bus rides, I would see who was online in Messenger and share photos and stories there with family and friends. I also posted frequently on my news feed.

25 mins ago - Technology

The future of music is (still) vinyl

Illustration: Sarah Grillo/Axios

Vinyl record sales are rising — and it's younger music enthusiasts who are driving the trend.

The big picture: Even though streaming services dominate music consumption, vinyl hasn't gone the way of CDs.